Synthaverse S.A.

WSE:SVE 株式レポート

時価総額：zł355.6m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Synthaverse マネジメント

マネジメント 基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Mieczyslaw Starkowicz

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間1.8yrs
CEOの所有権0.2%
経営陣の平均在職期間データなし
取締役会の平均在任期間2.9yrs

経営陣の近況

Recent updates

Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Apr 20
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

Apr 18
Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

Oct 14
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

Nov 29
More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Nov 16
We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

May 02
Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

Mar 08
Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Jan 29
What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 03
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

Dec 07
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

CEO（最高経営責任者

Mieczyslaw Starkowicz

1.8yrs

在職期間

Mr. Mieczyslaw Starkowicz serves as President of the Management Board and Chief Executive Officer at Synthaverse S.A. (formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.) since August 202...

取締役

名称ポジション在職期間報酬所有権
Waldemar Sierocki
Secretary of Supervisory Board & Member of Supervisory Boardno datazł24.00k6.48%
PLN 23.1m
Konrad Miterski
Member of the Supervisory Boardno datazł42.00k0.072%
PLN 256.3k
Wiktor Napióra
Vice Chairman of the Supervisory Boardno datazł40.00k7.2%
PLN 25.6m
Dariusz Kucowicz
Member of Supervisory Board16.4yrszł39.00k0.31%
PLN 1.1m
Maciej Korniluk
Member of Supervisory Board1.4yrsデータなしデータなし
Jaroslaw Blaszczak
Chairman of the Supervisory Boardno datazł113.00k2%
PLN 7.1m
Dirk Pamperin
Member of the Supervisory Board4.3yrszł37.00kデータなし
Maciej Siedlar
Member of Supervisory Board1.4yrsデータなし0.14%
PLN 506.9k

2.9yrs

平均在職期間

経験豊富なボード: SVEの 取締役会 は 経験豊富 ではない ( 2.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。